Sabby Management’s Foamix Pharmaceuticals Ltd. Ordinary Shares FOMX Stock Holding History

Sabby Management’s Portfolio FOMX Stock Details FOMX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-35,037	Closed	-$173K	–	284
2017 Q1	$173K	Sell	35,037 -23,301	-40%	-$224K	0.01%	221
2016 Q4	$648K	Sell	58,338 -143,226	-71%	-$1.35M	0.04%	178
2016 Q3	$1.87M	Sell	201,564 -52,142	-21%	-$436K	0.07%	135
2016 Q2	$1.61M	Sell	253,706 -6,694	-3%	-$44.4K	0.08%	121
2016 Q1	$1.7M	Buy	260,400 +22,000	+9%	+$142K	0.08%	116
2015 Q4	$1.93M	Sell	238,400 -4,961	-2%	-$37.1K	0.11%	127
2015 Q3	$1.78M	Buy	243,361 +67,361	+38%	+$687K	0.07%	171
2015 Q2	$1.8M	Buy	176,000 +160,700	+1,050%	+$1.78M	0.07%	173
2015 Q1	$142K	Sell	15,300 -148,000	-91%	-$1.32M	0.01%	269
2014 Q4	$1.15K	Sell	163,300 -107,900	-40%	-$617K	0.04%	152
2014 Q3	$1.48K	Buy	+271,200	New	+$1.56M	0.06%	134

Other funds holding FOMX

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

DSC Advisors Chicago, Illinois $11M AUM 5.88% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Axa Paris, France $256M AUM 25.01% 1-Year Est. Return

TCM

Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Sabby Management's FOMX Position: Q2 2017 in Review

Sabby Management sold out of Foamix Pharmaceuticals Ltd. Ordinary Shares (FOMX) in Q2 2017, closing a stake of 35,037 shares — an estimated $173K sold.

Sabby Management first reported a position in FOMX in Q3 2014 and held it in 11 quarters. The position peaked at $1.93M in Q4 2015. 56 funds tracked by Wall St. Rank hold FOMX as of Q2 2017.

Sabby Management reported no remaining Foamix Pharmaceuticals Ltd. Ordinary Shares position as of Q2 2017 after selling out during the quarter.
Sabby Management sold 35,037 Foamix Pharmaceuticals Ltd. Ordinary Shares shares in Q2 2017, an estimated $173K.
Sabby Management first reported a position in Foamix Pharmaceuticals Ltd. Ordinary Shares in Q3 2014 and held it in 11 quarters.
Sabby Management's Foamix Pharmaceuticals Ltd. Ordinary Shares position peaked at $1.93M in Q4 2015.
56 funds tracked by Wall St. Rank held Foamix Pharmaceuticals Ltd. Ordinary Shares as of Q2 2017.

Based on Sabby Management's 13F filing for Q2 2017, filed 14 Aug 2017.